← Back to patent-cliff list
CAS 118289-22-8
(Z)-4-((4-(1,3-dioxolan-2-yl)pyridin-2-yl)oxy)but-2-en-1-amine
Codes: LAFU-008
Application context (from source-drug indications)
Duodenal ulcerLafutidineGastric ulcerLafutidineGastro-oesophageal reflux diseaseLafutidinePeptic ulcerLafutidine
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Lafutidine | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
2-bromo-4-(1,3-dioxolan-2-yl)pyridine→(Z)-4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-en-1-ol→(Z)-4-(1,3-dioxolan-2-yl)-2-((4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-en-1-yl)oxy)pyridine→(Z)-4-((4-(1,3-dioxolan-2-yl)pyridin-2-yl)oxy)but-2-en-1-amine→4-nitrophenyl 2-((furan-2-ylmethyl)sulfinyl)acetate→(Z)-N-(4-((4-(1,3-dioxolan-2-yl)pyridin-2-yl)oxy)but-2-en-1-yl)-2-((furan-2-ylmethyl)sulfinyl)acetamide→(Z)-N-(4-((4-formylpyridin-2-yl)oxy)but-2-en-1-yl)-2-((furan-2-ylmethyl)sulfinyl)acetamide
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.